

Appendix 2 (as supplied by the authors): Additions discussed based on frequently prescribed medications in the clinic audits

Suggested Change	Collaborative Recommendation	Collaborative GRADE	Final Decision
Zopiclone should be added to the list.	Weakly against addition	Moderate	Zopiclone was not added to the list.
Varenicline should be added to the list.	Strongly for addition	High	Varenicline was added to the list.
Vitamin B12 should be added to the list.	Strongly for addition	Moderate	Vitamin B12 was added to the list.
Tretinoin should be added to the list.	Weakly for addition	Moderate	Tretinoin should be added to the list.
Baclofen should be added to the list.	Weakly for addition	Low	Baclofen was added to the list.
Pramoxine/zinc should be added to the list.	Weakly against addition	Very Low	Pramoxine/zinc was not added to the list.
Benztropine should be added to the list.	Weakly for addition	Low	Benztropine was added to the list.
Fusidic acid should be added to the list.	Weakly for addition	Moderate	Fusidic acid was added to the list.
Mupirocin should be added to the list.	Strongly for addition	Moderate	Mupirocin was added to the list.
Olopatadine should be added to the list.	Weakly for addition	Moderate	Olopatadine was added to the list.
Cromolyn should be added to the list.	Weakly against addition	Moderate	Cromolyn was not added to the list.
Montelukast should be added to the list.	Weakly against addition	Moderate	Montelukast was not added to the list.
Calcium should be added to the list.	Weakly against addition	Moderate	Calcium was not added to the list.
Vaginal ring eluting etonogestrel and ethinyl estradiol should be added to the list.	Weakly for addition	Moderate	Vaginal ring eluting etonogestrel and ethinyl estradiol was added to the list.
Conjugated estrogens should be added to the list.	Strongly for addition	Moderate	Conjugated estrogens were added to the list
Estradiol (17 β) should be added to the list.	Weakly for addition	Moderate	Estradiol (17 β) was added to the list.